kazusamycin A: from Streptomyces sp.No. 81-484 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11272917 |
| CHEMBL ID | 207141 |
| MeSH ID | M0125578 |
| Synonym |
|---|
| 3-hydroxyleptomycin b |
| kazusamycin a |
| 2,10,12,16,18-nonadecapentaenoic acid, 19-(3,6-dihydro-3-methyl-6-oxo-2h-pyran-2-yl)-17-ethyl-6-hydroxy-9-(hydroxymethyl)-3,5,7,11,15-pentamethyl-8-oxo- |
| CHEMBL207141 |
| unii-9f2y3169ip |
| 92090-94-3 |
| 9f2y3169ip , |
| pd-114721 |
| kazusamycin a, (-)- |
| cl-1957b |
| (2e,5s,6r,7s,9s,10e,12e,15r,16z,18e)-19-((2s,3s)-3,6-dihydro-3-methyl-6-oxo-2h-pyran-2-yl)-17-ethyl-6-hydroxy-9-(hydroxymethyl)-3,5,7,11,15-pentamethyl-8-oxo-2,10,12,16,18-nonadecapentaenoic acid |
| 2,10,12,16,18-nonadecapentaenoic acid, 19-((2s,3s)-3,6-dihydro-3-methyl-6-oxo-2h-pyran-2-yl)-17-ethyl-6-hydroxy-9-(hydroxymethyl)-3,5,7,11,15-pentamethyl-8-oxo-, (2e,5s,6r,7s,9s,10e,12e,15r,16z,18e)- |
| Q27896151 |
| (2e,5s,6r,7s,9s,10e,12e,15r,16z,18e)-17-ethyl-6-hydroxy-9-(hydroxymethyl)-3,5,7,11,15-pentamethyl-19-((2s,3s)-3-methyl-6-oxo-3,6-dihydro-2h-pyran-2-yl)-8-oxononadeca-2,10,12,16,18-pentaenoic acid |
| (2e,5s,6r,7s,9s,10e,12e,15r,16z,18e)-17-ethyl-6-hydroxy-9-(hydroxymethyl)-3,5,7,11,15-pentamethyl-19-[(2s,3s)-3-methyl-6-oxo-2,3-dihydropyran-2-yl]-8-oxononadeca-2,10,12,16,18-pentaenoic acid |
| kazusamycin a from streptomyces sp. |
| DTXSID801098454 |
| (2e,5s,6r,7s,9s,10e,12e,15r,16z,18e)-19-[(2s,3s)-3,6-dihydro-3-methyl-6-oxo-2h-pyran-2-yl]-17-ethyl-6-hydroxy-9-(hydroxymethyl)-3,5,7,11,15-pentamethyl-8-oxo-2,10,12,16,18-nonadecapentaenoic acid |
| HY-130044 |
| CS-0104446 |
| AKOS040745938 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID265700 | Toxicity in BALB/c mouse at 0.125 mg/kg, ip | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12 | Design, synthesis, and evaluation of novel kazusamycin A derivatives as potent antitumor agents. |
| AID265701 | Toxicity in BALB/c mouse at 0.25 mg/kg, ip | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12 | Design, synthesis, and evaluation of novel kazusamycin A derivatives as potent antitumor agents. |
| AID265703 | Hepatic toxicity in BALB/c mouse at 0.125 mg/kg, ip | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12 | Design, synthesis, and evaluation of novel kazusamycin A derivatives as potent antitumor agents. |
| AID265699 | Cytotoxicity against human HPAC cell line | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12 | Design, synthesis, and evaluation of novel kazusamycin A derivatives as potent antitumor agents. |
| AID265702 | Toxicity in BALB/c mouse at 0.5 mg/kg, ip | 2006 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12 | Design, synthesis, and evaluation of novel kazusamycin A derivatives as potent antitumor agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8 (72.73) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||